Univest
Univest
  • Markets

Max Healthcare Share Price Jumps 3.75% and Apollo Hospitals Rises 5.3% to a 52-Week High After Macquarie’s Double Upgrade to Outperform on 20 November 2026

  • November 20, 2026
  • Posted by: Neeraj Pandey
  • Category: News
No Comments
Max Healthcare Share Price Jumps 3.75% and Apollo Hospitals Rises 5.3% to a 52-Week High After Macquarie's Double Upgrade to Outperform on 20 November 2026

Max Healthcare Rs 1,079.65, up 3.75%. Apollo Hospitals Rs 9,201.50, up 5.30%, 52-week high. Macquarie: Outperform. Targets Rs 1,450 and Rs 10,500 (12:38 PM, 20 Nov).

Quick Answer

Max Healthcare share price rose 3.75% to Rs 1,079.65 on NSE at 12:38 PM on 20 November 2026, while Apollo Hospitals climbed 5.30% to Rs 9,201.50 and hit a 52-week high. The rally came after Macquarie upgraded both hospital chains by two notches, to Outperform from Underperform. The brokerage set targets of Rs 1,450 for Max Healthcare and Rs 10,500 for Apollo Hospitals, citing stabilising earnings, better use of new beds and easing valuation concerns.

The Max Healthcare share price rose sharply on Friday after global brokerage Macquarie turned bullish on India’s listed hospital chains. Max Healthcare gained 3.75% to Rs 1,079.65 on NSE at 12:38 PM, after touching an intraday high of Rs 1,090.

Rival Apollo Hospitals did even better, rising 5.30% to Rs 9,201.50 and hitting a fresh 52-week high of Rs 9,245. Both stocks were among the top gainers in the healthcare pack as the market weighed a rare double upgrade from a brokerage that had been bearish on the sector for most of the year.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Macquarie Upgrade: What Changed
  • Why Macquarie Turned Bullish on Hospital Stocks
    • Earnings Have Stabilised
    • New Beds Are Filling Up
    • Valuation Concerns Have Eased
  • Max Healthcare Share Price: What the Upgrade Means
  • Apollo Hospitals Share Price Hits a 52-Week High
  • How Other Hospital Stocks Traded
  • Should Investors Buy Hospital Stocks Now?
  • Conclusion
  • Frequently Asked Questions
    • Why is Max Healthcare share price rising today?
    • What is Macquarie’s target price for Max Healthcare?
    • What is Macquarie’s target price for Apollo Hospitals?
    • Did Apollo Hospitals hit a 52-week high today?
    • What does a double upgrade mean?
    • Why did Macquarie upgrade hospital stocks?
    • Should I buy Max Healthcare shares after the upgrade?

Macquarie Upgrade: What Changed

The Macquarie upgrade moved both stocks two notches higher, from Underperform straight to Outperform. That is a big shift in tone. In January, the brokerage had an Underperform call on both, with targets of Rs 825 for Max Healthcare and Rs 6,230 for Apollo Hospitals.

The new targets are far higher, at Rs 1,450 for Max Healthcare and Rs 10,500 for Apollo Hospitals. Based on the 12:38 PM prices, that implies potential upside of roughly 34% for the Max Healthcare share price and about 14% for Apollo.

Stock Price (12:38 PM) Change Old Call New Call New Target
Max Healthcare Rs 1,079.65 Up 3.75% Underperform, Rs 825 Outperform Rs 1,450
Apollo Hospitals Rs 9,201.50 Up 5.30% Underperform, Rs 6,230 Outperform Rs 10,500

Why Macquarie Turned Bullish on Hospital Stocks

Macquarie’s case rests on three points. Each one addresses a worry that had kept the brokerage cautious on hospital stocks earlier in the year.

Earnings Have Stabilised

Hospital chains went through a period of uneven growth as they spent heavily on new capacity. Macquarie now sees earnings stabilising, which lowers the risk of downgrades and gives investors more confidence in near-term numbers. For the Max Healthcare share price, steadier earnings matter because the company has been adding beds at a fast pace.

New Beds Are Filling Up

New hospitals usually run at low occupancy in their first few years and drag on margins. Macquarie expects capacity utilisation to keep improving as recently added bed capacity fills up, which should lift revenue per bed and operating margins over time.

Valuation Concerns Have Eased

Earlier in the year, Macquarie felt the sector’s valuation had run ahead of earnings. With profits catching up and the stocks having consolidated, the brokerage believes the risk-reward has turned favourable again.

Screen Healthcare Stocks on the Univest Screener

Max Healthcare Share Price: What the Upgrade Means

The Max Healthcare share price had lagged for much of the year as investors worried about the pace of expansion and the time new hospitals take to turn profitable. The upgrade signals that a large foreign brokerage now believes those concerns are priced in.

An Outperform rating means Macquarie expects the stock to beat the broader market over its rating horizon. The target price of Rs 1,450 is the most aggressive part of the call, and the stock would need to rise about a third from current levels to get there. Whether it does will depend on how quickly new beds ramp up and how stable occupancy stays across its network.

Apollo Hospitals Share Price Hits a 52-Week High

The Apollo Hospitals share price reached Rs 9,245 during the session, its highest level in a year. Apollo is India’s largest listed hospital chain and also runs pharmacies and a digital health business, which gives it more revenue streams than most peers.

Apollo’s target implies smaller upside than Max, partly because the stock has already run up closer to the brokerage’s fair value. Still, a fresh 52-week high on the back of an upgrade usually draws momentum buyers, and the stock outpaced the Max Healthcare share price in percentage terms on Friday.

How Other Hospital Stocks Traded

The upgrade lifted sentiment beyond the Max Healthcare share price and Apollo. Narayana Hrudayalaya rose 4.43% to Rs 1,956, while Fortis Healthcare gained 1.04% to Rs 818.25 by midday. Healthcare was among the stronger pockets of the market even as gold-linked and metal stocks came under pressure.

Download the Univest iOS App or Univest Android App to track hospital and healthcare stocks with daily expert research.

Should Investors Buy Hospital Stocks Now?

A brokerage upgrade is one input, not a reason to buy on its own. The Max Healthcare share price has already moved sharply on the news, so new buyers may want to wait for the initial excitement to settle.

Investors should track quarterly occupancy, average revenue per occupied bed and margins at new hospitals. These numbers will show whether Macquarie’s view plays out for the Max Healthcare share price and for Apollo. Long-term investors who believe in India’s demand for quality healthcare may prefer to build positions in stages rather than chase a single-day rally.

Conclusion

The Max Healthcare share price rose 3.75% and Apollo Hospitals hit a 52-week high after Macquarie’s double upgrade to Outperform. With targets of Rs 1,450 and Rs 10,500, the brokerage is betting that stable earnings, improving bed utilisation and easier valuations will drive the next leg of growth for India’s hospital chains. Of the two, the Max Healthcare share price has more room to Macquarie’s target.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why is Max Healthcare share price rising today?

Ans. Max Healthcare share price rose 3.75% to Rs 1,079.65 on 20 November 2026 after Macquarie upgraded the stock by two notches to Outperform from Underperform. The brokerage raised its target price to Rs 1,450, citing stable earnings and better use of new beds.

What is Macquarie’s target price for Max Healthcare?

Ans. Macquarie has set a target price of Rs 1,450 for Max Healthcare. That implies the Max Healthcare share price could rise about 34% from the 12:38 PM price of Rs 1,079.65. In January, the brokerage’s target was Rs 825.

What is Macquarie’s target price for Apollo Hospitals?

Ans. Macquarie’s new target for Apollo Hospitals is Rs 10,500, up from Rs 6,230 in January. The stock traded at Rs 9,201.50 at 12:38 PM on 20 November 2026, implying upside of about 14%.

Did Apollo Hospitals hit a 52-week high today?

Ans. Yes. Apollo Hospitals touched an intraday high of Rs 9,245 on 20 November 2026, a fresh 52-week high, after rising more than 5% on the Macquarie upgrade.

What does a double upgrade mean?

Ans. A double upgrade means a brokerage moves its rating up by two levels at once. In this case, Macquarie skipped the Neutral rating and moved both stocks straight from Underperform to Outperform, which signals a sharp change in its view.

Why did Macquarie upgrade hospital stocks?

Ans. Macquarie cited three reasons: hospital earnings have stabilised, capacity utilisation at new facilities is improving, and valuation concerns have eased as profits caught up with share prices. The call lifted both the Max Healthcare share price and Apollo Hospitals on 20 November 2026.

Should I buy Max Healthcare shares after the upgrade?

Ans. The upgrade is a positive signal, but the Max Healthcare share price has already moved sharply. Investors should look at occupancy trends, margins at new hospitals and their own risk appetite before deciding, and may prefer to buy in stages rather than in one go.



Apollo Hospitals share price Brokerage Upgrade Healthcare stocks Hospital stocks Macquarie Max Healthcare share price
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply